CSTL
Castle Biosciences Inc

1,010
Mkt Cap
$1.16B
Volume
410,788.00
52W High
$42.18
52W Low
$14.59
PE Ratio
-90.58
CSTL Fundamentals
Price
$40.77
Prev Close
$39.64
Open
$39.61
50D MA
$37.67
Beta
1.07
Avg. Volume
363,983.77
EPS (Annual)
$0.6236
P/B
2.55
Rev/Employee
$436,358.74
News
all
press releases
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of "Moderate Buy" by Analysts
Shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eight ratings firms that are presently covering the firm...
MarketBeat·8d ago
News Placeholder
More News
News Placeholder
AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's Agitation
Axsome stock jumps as the FDA grants priority review to sNDA for AXS-05 in Alzheimer's agitation, with a decision expected April 30, 2026.
Zacks·13d ago
News Placeholder
INSM Stock Up 78% in 6 Months: Here's What You Need to Know
Insmed shares surged on FDA and EU approvals of Brinsupri, strong uptake, and a growing pipeline which fueled optimism around its revenue outlook.
Zacks·13d ago
News Placeholder
RARE Rises on Completion of Rolling Submission for AAV Gene Therapy
Ultragenyx jumps after completing rolling BLA submission to the FDA for DTX401, an AAV gene therapy that could become the first approved treatment for GSDIa.
Zacks·15d ago
News Placeholder
RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint
Ultragenyx and Mereo BioPharma shares fall as phase III Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta miss primary endpoints.
Zacks·16d ago
News Placeholder
Kyverna Therapeutics Stock Up 41% in a Month: Here's Why
KYTX's shares surge after positive phase II data showed its CAR T miv-cel delivered major mobility gains in stiff person syndrome.
Zacks·16d ago
News Placeholder
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 830 Shares of Stock
Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek Maetzold sold 830 shares of Castle Biosciences stock in a transaction that occurred on Monday, December 22nd. The shares were...
MarketBeat·16d ago
News Placeholder
Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 830 Shares
Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek Maetzold sold 830 shares of the stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of...
MarketBeat·16d ago
News Placeholder
Take the Zacks Approach to Beat the Markets: Castle Biosciences, Hamilton Insurance & Monster Beverage in Focus
Castle Biosciences surged 77.9% after a Zacks upgrade, highlighting how the firm's stock picks outpaced the broader market in recent months.
Zacks·17d ago
News Placeholder
Ocugen Stock Surges 75% Year to Date: What's in Store for 2026?
Ocugen rises 75% YTD as it advances three gene therapies, with multiple phase II/III readouts and filings lined up for 2026.
Zacks·17d ago
<
1
2
...
>

Latest CSTL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.